Cooley advised AN2 Therapeutics on the offering, and Davis Polk advised the sales agent.AN2 Therapeutics, Inc. announced the SEC-registered at-the-market offering of its common stock for…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
